{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T14:49:28Z","timestamp":1773586168163,"version":"3.50.1"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Big Health"}],"content-domain":{"domain":["www.plosmentalhealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Ment Health"],"abstract":"<jats:p>This study examines the cost-effectiveness and cost-benefit of a fully automated smartphone-delivered digital cognitive behavioral therapy (CBT) intervention for Generalized Anxiety Disorder (GAD). In a simulated Markov model, 100,000 individuals with GAD were studied under one of five (n = 20,000 per arm) treatments (digital CBT [Daylight], individual CBT, group CBT, pharmacotherapy, or no GAD treatment). Model inputs were determined from the literature and included direct treatment costs and disease costs. Net monetary benefit (NMB) determined whether digital CBT is cost-beneficial from both a private payer and societal perspective in the United States in 2020. Digital CBT was found to generate the lowest 12-month total cost ($167.02m) and the second highest number of total quality-adjusted life years (14,711.86). Digital CBT showed a positive NMB relative to each alternative treatment and to no treatment for GAD in both a payer and societal perspective. Relative to no treatment, the average NMB of digital CBT was $1,836.83 from the payer perspective and $4,126.88 from the societal perspective. Digital CBT generates the most value in both a payer and societal perspective, and results were robust to sensitivity analysis with respect to effectiveness, pricing, and attrition parameters.<\/jats:p>","DOI":"10.1371\/journal.pmen.0000116","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T20:09:56Z","timestamp":1724702996000},"page":"e0000116","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmen.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of automated digital CBT (Daylight) for generalized anxiety disorder: A Markov simulation model in the United States"],"prefix":"10.1371","volume":"1","author":[{"given":"Michael","family":"Darden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna R.","family":"Carl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper A. J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2936-7717","authenticated-orcid":true,"given":"Christopher B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"pmen.0000116.ref001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4088\/JCP.v60n0702","article-title":"The economic burden of anxiety disorders in the 1990s.","volume":"60","author":"PE Greenberg","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"pmen.0000116.ref002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe.","volume":"19","author":"CDBE2010 study group","year":"2012","journal-title":"Eur J Neurol"},{"key":"pmen.0000116.ref003","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.janxdis.2013.09.009","article-title":"Incremental direct medical expenditures associated with anxiety disorders for the U.S. adult population: evidence from the Medical Expenditure Panel Survey.","volume":"27","author":"E Shirneshan","year":"2013","journal-title":"J Anxiety Disord"},{"key":"pmen.0000116.ref004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2011.11.014","article-title":"Humanistic and economic burden of generalized anxiety disorder in North America and Europe","volume":"140","author":"DA Revicki","year":"2012","journal-title":"J Affect Disord"},{"key":"pmen.0000116.ref005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","article-title":"Anxiety Disorders in Primary Care: Prevalence, Impairment, Comorbidity, and Detection","volume":"146","author":"K Kroenke","year":"2007","journal-title":"Ann Intern Med"},{"key":"pmen.0000116.ref006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve\u2010month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.","volume":"21","author":"RC Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"pmen.0000116.ref007","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","year":"2013","edition":"5"},{"key":"pmen.0000116.ref008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/da.20257","article-title":"Human and economic burden of generalized anxiety disorder.","volume":"25","author":"DL Hoffman","year":"2008","journal-title":"Depress Anxiety."},{"key":"pmen.0000116.ref009","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/da.10065","article-title":"Generalized anxiety disorder: prevalence, burden, and cost to society.","volume":"16","author":"H-U Wittchen","year":"2002","journal-title":"Depress Anxiety"},{"key":"pmen.0000116.ref010","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4088\/JCP.09m05328gry","article-title":"Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"71","author":"AA Alegr\u00eda","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"pmen.0000116.ref011","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1017\/S0033291705006069","article-title":"Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"35","author":"BF Grant","year":"2005","journal-title":"Psychol Med"},{"key":"pmen.0000116.ref012","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/da.20074","article-title":"The cost of treating anxiety: the medical and demographic correlates that impact total medical costs.","volume":"21","author":"MD Marciniak","year":"2005","journal-title":"Depress Anxiety."},{"key":"pmen.0000116.ref013","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0022-3999(94)90145-7","article-title":"Cost of anxiety disorders: Impact of comorbidity.","volume":"38","author":"E Sou\u0115tre","year":"1994","journal-title":"J Psychosom Res"},{"key":"pmen.0000116.ref014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/archpsyc.1994.03950050015002","article-title":"DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey.","volume":"51","author":"H-U Wittchen","year":"1994","journal-title":"Arch Gen Psychiatry."},{"key":"pmen.0000116.ref015","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.clinthera.2009.06.004","article-title":"Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.","volume":"31","author":"BG Bereza","year":"2009","journal-title":"Clin Ther"},{"key":"pmen.0000116.ref016","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0033-3182(97)71478-6","article-title":"Utilization of Medical Specialists by Anxiety Disorder Patients.","volume":"38","author":"BL Kennedy","year":"1997","journal-title":"Psychosomatics."},{"key":"pmen.0000116.ref017","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4088\/JCP.09m05626blu","article-title":"Quality of and Patient Satisfaction With Primary Health Care for Anxiety Disorders.","volume":"72","author":"MB Stein","year":"2011","journal-title":"J Clin Psychiatry."},{"key":"pmen.0000116.ref018","article-title":"Clinical Practice Review for GAD.","year":"2015","journal-title":"Anxiety and Depression Association of America"},{"key":"pmen.0000116.ref019","first-page":"9S","article-title":"Clinical practice guidelines. Management of anxiety disorders.","volume":"51","author":"Canadian Psychiatric Association","year":"2006","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"key":"pmen.0000116.ref020","first-page":"617","article-title":"Diagnosis and management of generalized anxiety disorder and panic disorder in adults.","volume":"91","author":"AB Locke","year":"2015","journal-title":"Am Fam Physician"},{"key":"pmen.0000116.ref021","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1037\/0033-2909.131.5.785","article-title":"Meta-Analysis of Cognitive-Behavioral Treatments for Generalized Anxiety Disorder: A Comparison With Pharmacotherapy.","volume":"131","author":"K. Mitte","year":"2005","journal-title":"Psychol Bull."},{"key":"pmen.0000116.ref022","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"D Baldwin","year":"2014","journal-title":"J Psychopharmacol (Oxf)."},{"key":"pmen.0000116.ref023","doi-asserted-by":"crossref","DOI":"10.7326\/AITC201904020","article-title":"Generalized Anxiety Disorder","volume":"170","author":"J DeMartini","year":"2019","journal-title":"Ann Intern Med"},{"key":"pmen.0000116.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0033582","article-title":"The occasional case against broad dissemination and implementation: Retaining a role for specialty care in the delivery of psychological treatments.","volume":"69","author":"JS Comer","year":"2014","journal-title":"Am Psychol"},{"key":"pmen.0000116.ref025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cpr.2009.11.001","article-title":"Dissemination of cognitive-behavioral treatments for anxiety disorders: Overcoming barriers and improving patient access.","volume":"30","author":"RW Gunter","year":"2010","journal-title":"Clin Psychol Rev"},{"key":"pmen.0000116.ref026","article-title":"In: Demographics of Mobile Device Ownership and Adoption in the United States [Internet].","author":"Pew Research Center","year":"2021"},{"key":"pmen.0000116.ref027","article-title":"Designing and Delivering a DTx Clinical Research Program: No Need to Re-invent the Wheel.","author":"CA Espie","journal-title":"Digital Therapeutics: Scientific, Statistical, Clinical, and Regulatory Development Aspects."},{"key":"pmen.0000116.ref028","article-title":"Efficacy of digital cognitive behavioral therapy for moderate\u2010to\u2010severe symptoms of generalized anxiety disorder: A randomized controlled trial.","author":"JR Carl","year":"2020","journal-title":"Depress Anxiety."},{"key":"pmen.0000116.ref029","doi-asserted-by":"crossref","first-page":"101609","DOI":"10.1016\/j.jbtep.2020.101609","article-title":"Feasibility and efficacy of a digital CBT intervention for symptoms of Generalized Anxiety Disorder: A randomized multiple-baseline study.","volume":"70","author":"CB Miller","year":"2021","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"pmen.0000116.ref030","article-title":"Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions.","author":"D Jankovic","year":"2020","journal-title":"Appl Health Econ Health Policy."},{"key":"pmen.0000116.ref031","article-title":"Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis.","volume":"13","author":"S Kumar","year":"2018","journal-title":"PLoS ONE."},{"key":"pmen.0000116.ref032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/16506073.2018.1560358","article-title":"Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials.","volume":"49","author":"E Carl","year":"2020","journal-title":"Cogn Behav Ther"},{"key":"pmen.0000116.ref033","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1017\/S0033291715001427","article-title":"Economic evaluations of Internet interventions for mental health: a systematic review","volume":"45","author":"T Donker","year":"2015","journal-title":"Psychol Med"},{"key":"pmen.0000116.ref034","first-page":"1","article-title":"Internet-Deliv Cogn Behav Ther Major Depress Anxiety Disord.","volume":"19","author":"Health Quality Ontario","year":"2019"},{"key":"pmen.0000116.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2016.12.005","article-title":"Cost-effectiveness of interventions for treating anxiety disorders: A systematic review","volume":"210","author":"RH Ophuis","year":"2017","journal-title":"J Affect Disord"},{"key":"pmen.0000116.ref036","first-page":"1","article-title":"A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety.","volume":"3","author":"D Richards","year":"2020","journal-title":"Npj Digit Med"},{"key":"pmen.0000116.ref037","doi-asserted-by":"crossref","first-page":"109812","DOI":"10.1016\/j.jpsychores.2019.109812","article-title":"The cost-effectiveness of stepped care for the treatment of anxiety disorders in adults: A model-based economic analysis for the Australian setting.","volume":"125","author":"JA Stiles","year":"2019","journal-title":"J Psychosom Res"},{"key":"pmen.0000116.ref038","article-title":"York Health Economics Consortium [Internet].","author":"Markov Model","year":"2016"},{"key":"pmen.0000116.ref039","article-title":"In: Helping millions back to good mental health","author":"Big Health","year":"2021","journal-title":"Internet]"},{"key":"pmen.0000116.ref040","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/heapol\/czl018","article-title":"Calculating QALYs, comparing QALY and DALY calculations.","volume":"21","author":"F. Sassi","year":"2006","journal-title":"Health Policy Plan"},{"key":"pmen.0000116.ref041","article-title":"York Health Economics Consortium","author":"Net Monetary Benefit","year":"2016"},{"key":"pmen.0000116.ref042","article-title":"Net benefit framework.","author":"D Hartwell","year":"2011","journal-title":"NIHR Journals Library"},{"key":"pmen.0000116.ref043","unstructured":"Stata Statistical Software. College Station, TX: StataCorp LLC; 2017."},{"key":"pmen.0000116.ref044","volume-title":"Secondary Analysis of Electronic Health Records.","author":"M Komorowski","year":"2016"},{"key":"pmen.0000116.ref045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpr.2018.03.002","article-title":"Remission in CBT for adult anxiety disorders: A meta-analysis.","volume":"61","author":"KS Springer","year":"2018","journal-title":"Clin Psychol Rev."},{"key":"pmen.0000116.ref046","doi-asserted-by":"crossref","first-page":"d1199","DOI":"10.1136\/bmj.d1199","article-title":"Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis","volume":"342","author":"D Baldwin","year":"2011","journal-title":"BMJ"},{"key":"pmen.0000116.ref047","article-title":"Psychological therapies for generalised anxiety disorder.","author":"Cochrane Common Mental Disorders Group","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"pmen.0000116.ref048","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/da.10106","article-title":"Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: Findings in men and women from 8 years of follow-up.","volume":"17","author":"KA Yonkers","year":"2003","journal-title":"Depress Anxiety."},{"key":"pmen.0000116.ref049","article-title":"How Much More Than Medicare Do Private Insurers Pay? A Review of the Literature.","author":"E Lopez","year":"2020","journal-title":"KFF]"},{"key":"pmen.0000116.ref050","year":"2018","journal-title":"Internet]"},{"key":"pmen.0000116.ref051","article-title":"10 Years of Emergency Room Spending for the Commercially Insured.","author":"J Hargraves","year":"2019","journal-title":"Healthcostinstitute.org"},{"key":"pmen.0000116.ref052","article-title":"Inpatient stays involving mental and substance use disorders, 2016: Statistical brief# 249.","author":"PL Owens","year":"2019","journal-title":"Healthc Cost Util Proj HCUP Stat Briefs."},{"key":"pmen.0000116.ref053","article-title":"Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted.","year":"2020","journal-title":"U.S. Bureau of Labor Statistics"},{"key":"pmen.0000116.ref054","first-page":"963","article-title":"Differences in Medication Adherence and Healthcare Resource Utilization Patterns: Older versus Newer Antidepressant Agents in Patients with Depression and\/or Anxiety Disorders.","volume":"22","author":"DV Sheehan","year":"2008","journal-title":"CNS Drugs"},{"key":"pmen.0000116.ref055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-375678-7.00510-1","volume-title":"Encyclopedia of Health Economics.","author":"E. Nord","year":"2014"},{"key":"pmen.0000116.ref056","unstructured":"Simplepractice. In: Therapy Session Rates by CPT Code [Internet]. 13 Jun 2019 [cited 27 May 2021]. Available: https:\/\/marketing-wp-staging.simplepractice.com\/blog\/median-therapy-session-rates-by-state-and-city-cpt-codes\/."},{"key":"pmen.0000116.ref057","article-title":"Psychotherapy Codes for Psychologists","author":"American Psychological Association","year":"2018"},{"key":"pmen.0000116.ref058","unstructured":"CPT Code 90853: Appropriate Use. In: E2E Medical Billing Services [Internet]. 29 Sep 2020 [cited 27 May 2021]. Available: https:\/\/www.e2emedicalbilling.com\/blog\/cpt-code-90853-appropriate-use\/."},{"key":"pmen.0000116.ref059","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders.","volume":"19","author":"B Bandelow","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"pmen.0000116.ref060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1471-244X-11-193","article-title":"Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study.","volume":"11","author":"A Berger","year":"2011","journal-title":"BMC Psychiatry"},{"key":"pmen.0000116.ref061","unstructured":"Federal Upper Limits. In: Medicaid [Internet]. [cited 16 Apr 2020]. Available: https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/federal-upper-limits\/index.html."},{"key":"pmen.0000116.ref062","unstructured":"U.S. Bureau of Labor Statistics. 2021 [cited 5 Mar 2020]. Available: https:\/\/www.bls.gov\/."},{"key":"pmen.0000116.ref063","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3111\/13696991003591321","article-title":"Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis.","volume":"13","author":"C Fran\u00e7ois","year":"2010","journal-title":"J Med Econ"},{"key":"pmen.0000116.ref064","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/da.10131","article-title":"Medical and productivity costs of anxiety disorders: Case control study.","volume":"19","author":"M Marciniak","year":"2004","journal-title":"Depress Anxiety."},{"key":"pmen.0000116.ref065","article-title":"Cost-effectiveness of digital CBT (Sleepio) for insomnia: A Markov simulation model in the United States.","author":"M Darden","year":"2021","journal-title":"Sleep"},{"key":"pmen.0000116.ref066","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40261-017-0528-x","article-title":"Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review.","volume":"37","author":"MD Mochcovitch","year":"2017","journal-title":"Clin Drug Investig."},{"key":"pmen.0000116.ref067","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamapsychiatry.2023.3971","article-title":"Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials","volume":"81","author":"D Papola","year":"2024","journal-title":"JAMA Psychiatry"}],"container-title":["PLOS Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmen.0000116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T20:10:33Z","timestamp":1724703033000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmen.0000116"}},"subtitle":[],"editor":[{"given":"Juan Felipe","family":"Cardona","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmen.0000116","relation":{},"ISSN":["2837-8156"],"issn-type":[{"value":"2837-8156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}